Chemoresistance in Solid Tumours
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (25 August 2023) | Viewed by 2165
Special Issue Editors
Interests: colorectal cancer; epithelial-mesenchymal transition (EMT); molecular imaging
2. AntiCancer Inc., San Diego, CA 92111, USA
Interests: cancer research
Special Issue Information
Dear Colleagues,
Current precision medicine for solid tumours comprises a combination of appropriate cytotoxic agents and molecularly targeted drugs for each molecular subtype. Since molecular subtypes provide appropriate therapeutic targets, various molecular subtypes have been explored by gene mutation, gene expression, and protein expression. However, this tumour heterogeneity is considered one of the main reasons for chemoresistance, since refractory solid tumours exhibit high tumour heterogeneity and cannot be eliminated by several anticancer drugs. Although the cancer stem cell theory has been accepted as a model that can resolve tumour heterogeneity, tumour heterogeneity remains unresolved because cancer cells have the plasticity to revert from non-cancer stem cells to cancer stem cells. In addition, the microenvironment is one of the factors contributing to chemotherapeutic resistance in solid tumours. For example, pancreatic cancer has a predominance of stroma and few cancer cells, but this stroma acts as a barrier to the reach of anticancer drugs and hinders the infiltration of cytotoxic lymphocytes. The prognosis for patients with highly advanced solid tumours remains poor because tumour heterogeneity, the plasticity inherent in cancer cells, and the contribution of the microenvironment to chemotherapy resistance remain unresolved.
Therefore, this Special Issue of Cancers will highlight new research articles and timely review articles on novel therapies to resolve chemotherapy resistance in solid tumours.
Dr. Shuya Yano
Dr. Robert M. Hoffman
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- solid tumours
- heterogeneity
- chemotherapeutic resistance
